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Introduction – Diabetes is a growing health concern.  Diabetic retinopathy (DR), is a 
complication resulting from long-term diabetes and is currently the leading cause of blindness in 
the US.  The cause of pericyte loss, an early indiciator of DR progression, is currently unknown.  
Inflammation, increased in diabetes, could play a role in the progression of DR and be one of the 
causes of pericyte loss.    
 
Methods and Materials- Retinas from 3, 6, 12, 18, and 24 week Akita (AK) and DB mice were 
taken and cell counts, vasculature, and mRNA expression were examined.  Pericytes treated with 
IFN-γ and PDGF-BB in chronic and acute conditions and PDGFRβ signaling was determined 
using Western blot analysis.  Apoptosis and proliferation were examined using western blots and 
immunohistochemistry of IFN-γ treated pericytes.   
 
Results- Pericytes numbers were changed as 3 weeks in DB and Akita models. Proinflammatory 
markers increased at 6 weeks and displayed their maximum expression at 12 and 18 weeks.  
Chronic treatments with IFN-γ changed AKT and PKCδ activation and increases pericytes 
apoptosis.   
 
Discussion- Pericyte loss appears to begin prior to an increase in pro-inflammatory factors 
indicating that perhaps retinal inflammtion may not initiate pericyte loss or that loss of pericyte 
numbers at 3 weeks may be due to reduced numbers of neural crest cells migrating to vasculature 
or a reduced number of neural crest cells differentiating into pericytes.  Proinflammatory changes 
occur between 3-6 weeks in both Akita and DB models of diabetes; however, the peak levels in 
expression of proinflammtory markers differs between Akita and DB models.   
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One of the markers that increased very early in the progression of diabetic retinopathy, IFN-γ, 
triggered apoptosis in isolated retinal pericytes by increasing protein kinase Cδ activation, which 




Diabetes is a prevalent and growing health concern in the United States and across the 
world.  As of 2014, 30.3 million Americans and 422 million people worldwide have diabetes 
(American Diabetes Association, World Health Organization, 2017).  Of those 30.3 million 
people (9.4% of US population), 23.1 million are diagnosed with about 7.2 million people being 
undiagnosed (ADA, 2017).  It is estimated that 5% of those have type 1 diabetes and around 90-
95% of all diabetics are type 2 (ADA, 2017).  In the world, the rate of diabetes has currently 
doubled from 4.7% in 1980 to 8.5% in 2014 (WHO, 2017).  It is said globally that 1.6 million 
deaths can be directly linked to diabetes and 2.2 million can be linked indirectly to high blood 
glucose (WHO, 2017).   
Hyperglycemia, an excessive amount of blood glucose, is one of the major characteristics 
of diabetes. Hyperglycemia is the result of a loss of insulin production, secretion, insulin 
resistance, or a combination of all three (ADA, 2017).  There are two main types of diabetes, 
type 1 and type 2.  Type 1, also known as insulin-dependent and formerly juvenile-onset 
diabetes, is an autoimmune condition in which the immune system attacks the pancreatic beta 
cells leading to a loss in insulin production (CDC, 2011).  Type 2, formerly known as adult-
onset, is often attributed to insulin resistance, low insulin production, or a combination of both 
(CDC, 2011).  Insulin resistance is when the cells in the body do not respond to the insulin 
produced, often leading to an overproduction of insulin.  A third smaller type of diabetes is 
gestational diabetes in which 2-10% pregnant mothers have high blood sugar (CDC, 2011).  This 
can cause development of type 2 diabetes later in life of both the child and the mother.  One of 
the complications of diabetes is diabetic retinopathy (DR).  It is currently the leading cause of 
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blindness in American adults, with around 9 million Americans over the age of 40 suffering from 
DR and related diseases (Saadine, 2008).  In order to discuss the effect of diabetes on the eye, 




Figure 1  Image of major eye structures. Image from Glaucoma Research Foundation. (Eye Anatomy, 2017) 
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1.2 Retina and Eye 
  As shown in Figure 1, the affected area in patients suffering from DR lies in the retinal 
area, located in the back of the eye.  The function of the eye is to convert light into signals for the 
brain to produce images and pictures.  The retina contains photoreceptors that transform light 
into electrochemical impulses.     
 
Figure 2 Light transmission in the retina.  The 6 retinal layers along with information processing cells.  Image from 
Purves et al., 2001. 
 Light is absorbed by the rods and cones in the photoreceptor layer, as shown in Figure 2 
(Purves et al., 2001).  Following phototransduction, neurotransmitter is released onto the bipolar 
cells (and some horizontal cells) (Purves et al., 2001).  These bipolar cells transfer information 
through graded potentials to the ganglion cells (Purves et al., 2001).  The ganglion cells, whose 
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axons form the optic nerve along with glial cells, send vital information directly to the other 
areas of the central nervous system (CNS) (Purves et al., 2001).  Amacrine and horizontal cells 
are mostly used for lateral inhibition (Purvers et al., 2001).  The horizontal cell helps integrate 
and regulate information from multiple photoreceptors to the bipolar cells while amacrine cells 
do the same for the ganglion cells (Masland, 2012).  However, these are not the only cell types 
located in the retina.       
 
Figure 3 The location of retina within the eye.  The 6 different retinal layers.  Also, the location of blood-retinal 
barriers and how the barriers are perceived.   Image from Kaur et al., 2008. 
 As shown in Figure 3, the retina contains six layers with the two blood-retinal barriers 
(BRBs).   The BRB is a tight barrier that regulates ions, protein, and water flux inside and 
outside the retina (Cunha-Vaz et al., 2011). The outer blood-retinal barrier (oBRB) is made up of 
tight junctions from retinal pigmented epithelium (RPE) while the inner BRB (iBRB) is made up 
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of tight junctions between endothelial cells.  Some of the important cells types besides the 
neurons and endothelial cells are the Mϋller glial, astrocytes, pericytes, and microglia.  The 
Mϋller glia cell bodies are located in the inner nuclear layer, but they project their cellular 
processes through much of the other retinal layers, while the retinal astrocytes are located in the 
nerve fiber layer and their processes in the ganglion cell layer.  The macroglia, which includes 
astrocytes and Mϋller glia, act as support cells and their main functions are maintaining 
homeostasis and providing structural support (Hoz et al., 2016).  The microglia are located 
within the plexiform and nerve fiber layers and the microglia project their processes throughout 
the entire retina.  The microglia act as the innate immune cells of the central nervous system 
(CNS). 
The role of the endothelial cells is to form the vasculature of the retina while the pericytes 
are important in helping maintain the vasculature by acting as the support cells for the 
endothelial cells (Bergers and Song, 2005).  These cells all communicate with each other to keep 
homeostasis inside the retina.  Endothelial cells release platelet-derived growth factor 
homodimer subunit BB (PDGF-BB) which is important for the attraction and survival of 
pericytes.  Pericytes, likewise, release transforming growth factor beta (TGF-β) which is 
important for iBRB maintenance and endothelial cell survival.     
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1.3 Diabetic Retinopathy Stages 
There are 4 different stages which, in order of increasing intensity, are mild 
nonproliferative DR, moderate nonproliferative DR, severe nonproliferative DR, and 
proliferative diabetic retinopathy (PDR) (Wilkinson et al., 2003).  In the mild nonproliferative 
DR, pericyte loss leads to endothelial cell loss and areas of swellings (microaneurysms), which 
can then lead to fluid leakage and eventually fluid buildup within the retina (macular edema) 
(Wilkinson et al., 2003). In the moderate nonproliferative DR, there is the addition of bleeding in 
the eye (intraretinal hemorrhaging), neuronal loss, inflammation, gliosis, dead cell debris buildup 
(cotton wool spots), and lipid buildup from leaky blood vessels (hard exudates) (Wilkinson et al., 
2003).  In the severe stage, there is the addition of formation of intraretinal microvascular 
abnormality (IRMA’s) and the weakening of the blood vessel walls (venous beading) (Wilkinson 
et al., 2003).  In PDR, the hallmark of development is the formation of new, leaky blood vessels 
that can eventually lead to blindness (Wilkinson et al., 2003). 
 It is estimated that 35.4% of all diabetic patients worldwide get some form of DR while 
7.24% eventually develop PDR (Yau et al., 2012).  There are also differences in the occurrence 
of DR between type 1 and type 2 as 77% of all type 1 develop DR while only 25% of type 2 get 
DR (Yau et al, 2012).  This is magnified by the duration of diabetes as 86% of all type 1 
diabetics with over 20 years of having diabetes develop DR while only 52% of all type 2 
diabetics get DR with the same length of time (Yau et al., 2012).  Type 1 diabetics that have 
diabetes over 20 years have 40.36% chance of getting PDR, while type 2 diabetics with over 20 
years of diabetes only have a 15.13% chance of getting PDR (Yau et al., 2012).  This could be 
due to differences in blood pressure, diabetes duration, and cause of disease.  In order to study 
differences between the two types of diabetes, there are two main mouse models. 
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1.4 Diabetic Mouse Models 
This study employs two different mouse models to emulate the two different diabetes 
types Ins2Akita (AK or Akita) and the Leprdb(db/db or DB) model.  The diabetes that develops in 
Akita mice is similar to type 1 diabetes in humans, while the homozygous DB mice develop 
diabetes that is similar to type 2 diabetes in humans (Robinson et al., 2012).  The Akita mice 
have a missense mutation in the insulin 2 gene that results in pancreatic beta-cell toxicity and 
dysfunction (Wang et al., 1999). A mutation in the leptin receptor gene which results in a 
dysfunction in signaling to the hypothalamus, resulting in obesity, mild diabetes, islet 
hyperplasia, and hyperinsulinemia in the DB mice (Coleman, 1978). Both models are maintained 
on a C57BL/6J background (WT).  As is the case with the different types of DR, the two mouse 
models have different progression of diabetes and DR. 
 The Akita mice are not obese and the disease develops due to an autosomal dominant 
trait.  The Akita mice develop hyperglycemia and hypoinsulinemia around 4 to 6 weeks of age 
along with extreme thirst (polydipsia) and extreme urination (polyuria) (Yoshioka et al, 1997; 
Katsuda et al, 2013).  Around 6 months there is increased albumin excretion and glomerular 
hypertrophy (Katsuda et al, 2013).  The hyperglycemia can also cause oxidative stress and 
kidney injury in these animals (Ueno et al, 2002).  At 4 months of age, the Akita mice display 
increased vascular permeability (Barber et al., 2005). Around 6 months of age the Akita mice 
develop the early retinal abnormalities like vascular leakages, decreased retinal blood flow, and 
pericyte loss while are 9 months there are symptoms like microaneuryisms, and 
neovascularization (Zongchao et al., 2013; Alistar et al., 2005, Wright et al, 2012).  Around 5-10 
months, altered astrocyte and microglial morphology along with the apoptosis of retinal cells has 
been described (Zongchao et al, 2013; Alistar et al., 2005).  The average life span of the male 
8 
Akita mice however is 305 days or around 10 months while the average life span of the female 
Akita mice is the same as the C57BL/6J, so many of these retinal changes do not develop until 
near death for these mice (Yoshioka et al., 1997).     
 In the DB mice, there is a severe increase of blood glucose and insulin levels 4-6 weeks 
of age (Coleman, 1978).  At even 3-4 weeks of age, the mice are bigger than their WT litter 
mates.  These mice can range from transient to progressive hyperglycemia and these are 
correlated with pancreatic β cell necrosis and islet atrophy like their type 2 counterparts in 
humans (Katsuda et al, 2013)  At around 5 months the DB mice have decreased creatinine 
clearance and increased albumin in the urine (albuminuria) (Allen et al., 2004; Sharma et al., 
2003).  Like the Akita mice, DB mice also have pericyte and endothelial cell loss, increased 
blood flow, and basement membrane thickening at 6 months of age (Midena et al., 1989; 
Clements et al., 1998; Tadoyoni et al., 2003).  The earliest time point found for formation of 
acellular capillaries is at 34 months as described by Chou et al., and around 15 months, there is 
BRB breakdown, and possible neovascularization (Chou et al., 2014; Cheung et al., 2005).  
However, the average life span of male DB mice is around 349 days or 12 months while the 
female DB mice life span is around 487 days or 16 months and thus, like the Akita mice, many 




Figure 4.  Chart of relation between hyperglycemia and effects upon DR.   Hyperglycemia effects upon factors that 
lead to endothelia cell loss and eventually vision loss.  The stages of DR along in relation to the cellular dysfunction.  
Taken from Robinson et al., 2012. 
1.5 Hyperglycemia effects upon DR 
The exact mechanism whereby increased blood glucose (hyperglycemia) initiates 
vascular and neuronal alterations is not well understood. Figure 4 shows some proposed 
mechanisms (Curtis et al., 2009, Villarroel et al., 2009, Robinson et al., 2012).  Hyperglycemia 
can induce many things like; oxidative stress, advanced glycation end products (AGEs), protein 
kinase C (PKC) activation, increased flux through the polyol pathway, and inflammation, though 
there has been no human studies examining these yet (Robinson et al, 2012; Frank, 2004; 
Cheung et al., 2010).  These different mechanisms can then eventually lead to pericyte apotosis. 
Hyperglycemia causes the activation of the polyol pathway.  Polyol initiates the reduction 
of glucose to sorbitol and then is metabolized to fructose (Oates, 2002).  The fructose produced 
can then be converted to fructose-3-phosphate and 3-deoxyglucosone, both of which are 
powerful glycosylating agents, which increases the formation of AGEs (Szwergold et al., 1990).  
The increase of glycosylating agents along with the glucose itself forming covalent bonds with 
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the protein (glycation) results in AGEs formation.  This glycosylation, along with the non-
enzymatic glycosylation of proteins often results in disrupted function including the alteration of 
enzyme activity, decreased receptor recognition, molecular conformation changes, and can lead 
to a non-functional protein (Hsieh et al., 2007).  The increase of fructose and sorbitol along with 
the formation of AGEs can increase the amount of reactive oxygen species (ROS) (Drummond et 
al., 2011; Lassègue et al., 2003).  Glycation has been shown to decrease platelet derived growth 
factor homodimer subunit BB (PDGF-BB) activity in-vitro, which may eventually lead to 
pericyte cell death (Nass et al., 2010; Stitt et al., 2004).   
Receptor for advanced glycation end products (RAGE) is present on many cells in the 
body, including some pericytes, endothelial cells, microglia, and Müller glia cells.  AGEs and the 
increase of ROS are toxic to pericytes and can cause cell death (apoptosis) (Chibber et al., 1997).  
AGEs can also cause more oxidative stress, inhibition of protein kinase B (AKT) 
phosphorylation, and reduced platelet derived growth factor ββ (PDGFβ) signaling (Stitt et al., 
2004).  AGEs can also cause an upregulation of VEGF leading to an increase of 
neovascularization and angiogenesis (Singh et al., 2014).   
These different mechanisms can cause release or alter activation of growth factors like 
vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), cytokines 
like interferon gamma (IFN-γ) or interleukin 6 (IL-6) or directly cause dysfunction of cells like 
pericytes or astrocyte activation.  The loss of pericyte is often the first sign of DR. Pericyte loss 
can then lead to vascular permeability which then can start the DR cascade chain of events.   
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1.6 PDGFRβ Signaling Pathway      
One of the important factors altered by hyperglycemia are growth factors, including 
platelet-derived growth factors (PDGFs).   
 
Figure 5 Chart of all PDGF ligands, receptors, and functions of the receptors.  PDGF homo and heterodimers along 
with the homo and hetero receptors and the downstream functions.  Taken from Cao, 2013. 
As seen from Figure 5, PDGF are a family of polypeptides that can form homo or 
heterodimers (Cao et al., 2013).  The homo or hetero dimers, like PDGF-AA can then bind to the 
homodimerized receptor, PDGFRββ or PDGFRαα, or heterodimerized receptor PDGFRαβ (Cao 
et al., 2013). Not all cells contain all receptors. Pericytes express PDGFRβ; however, astrocytes 
express only PDGFRα.  Platelet derived growth factor homodimer subunit BB (PDGF-BB) is 
important for the not only pericyte viability but important for maintaining the vasculature of the 
eye.  Loss of PDGF-BB in mice often results in vascular abnormalities, increased pericyte loss, 
capillary dilation, and endothelial cell hyperplasia (Leveen et al., 2004; Lindahl et al., 1994; 
Hellstrom et al., 1999; Hellstrom et al., 2001, Hammes et al., 2002).  Hyperglycemia can induce 
src homology domain 2 containing inositol-5-phosphatase (SHP-1) resulting in de-
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phosphorylation of the receptor and leading to increased pericyte apoptosis (Geraldes et al., 
2009).  PDGFRβ signaling results in activation of two major pathways the phosphoionositide 3-
kinase (PI3K) / protein kinase B (AKT) pathway and the mitogen-activated protein kinase 
(MAPK)/ extracellular signal-regulated kinases (ERK) pathways that results in the proliferation 
and survival signaling in pericytes as seen in Figure 6.    
 
Figure 6 PDGF-BB Downstream activation of ERK and AKT pathways.  PDGF-BB phosphorylation leads to 
activation of ERK and AKT which regulate cell proliferation and survival.  Taken from Deuse et al., 2010. 
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Figure 7.  PI3K/AKT signaling pathway. Taken from Diehl and Schall 2013 
1.7 PI3K/AKT Signaling Pathway 
Ligand binding to the PDGFRβ results in the activation of PI3K, leading to 
phosphorylation of membrane bound phosphatidylinositol (PtdIns), in this case 
phosphatidylinositol 4,5-bisphosphate (PIP2), converting it into phosphatidylinositol-3,4,5-
trisphosphate (PIP3).  This can cause cytosolic AKT to dock to PIP3  and opening of the tyrosine 
phosphorylation site to phosphoinositide-dependent kinase (PDK1) and serine phosphorylation 
site by mammalian target of rapamycin complex 2 (mTORC2) (Diehl and Schall, 2013).  AKT 
can also be stimulated through a PI3K-independent pathway using DNA-dependent protein 
kinase (DNA-PK) (Diehl and Schall, 2013).  The phosphorylation of AKT then causes it to 
translocate to the cytosol and nucleus where many of the downstream targets are found 
(Nicholson and Anderson, 2002).   
AKT can upregulate proliferation signaling, and also downregulate apoptotic signaling 
(Brunet et al., 2001).  The downstream target phosphorylation tuberous sclerosis protein 2 
(TSC2) which leads to a deactivation of TSC2 and upregulation of mTORC1, which then results 
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in increased transcription and increased mitochondrial activity (Zarogoulidis et al, 2014).  AKT 
also inactivates glycogen synthase kinase 3 (GSK3), resulting in the prevention of cyclin D1 
degradation, and thus causing promotion of the cell to undergo G1 phase progression (Alao, 
2007).  AKT inhibits Bcl-2-associated death promoter (BAD) and transcription factor Forkhead 
Box O (FOXO), both which promote apoptosis.  AKT can also be deregulated directly or 
indirectly.  Phosphatase and tensin homolog (PTEN) and src homology domain 2 containing 
inositol-5-phosphatase (SHIP1) both can dephosphorylate PIP3 while protein phosphatase 2A 
(PP2A) or the H domain and leucine-rich repeat protein phosphatase (PHLPP) can 
dephosphorylate AKT directly (Diehl and Schall, 2013).   
 
Figure 8 RAS-RAF-MEK-ERK pathway. Taken from Johnson et al., 2014. 
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1.8 ERK Signaling Pathway 
The other pathway that PDGFRβ can activate is the MAP kinase kinase kinase (MAP3K) 
pathways seen in Figure 8.  There are multiple different MAPK pathways, each containing a 
cascade of kinases.  For the ERK pathway, the binding of PDGF-BB to the receptors causes 
phosphorylation by docking proteins such as growth factor receptor-bound protein 2 (GRB2) 
using the Src Homology 2 (SH2) domain.  The docking protein will then use SRC Homology 3 
(SH3) to bind to guanine nucleotide exchange factor (GEF) SOS that assists the small GTPAse 
RAS in exchanging GDP for GTP, a step that activates the RAS.  RAS then binds to and 
activates rapidly accelerated fibromosarcoma (RAF).  There a 3 different RAFs, Raf-1 proto-
oncogene (RAF1/CRAF), B-Raf proto-oncogene, and Serine/threonine-protein kinase (A-Raf), 
all of which activate mitogen activated protein kinase kinase (MEK).  This MEK can then 
directly phosphorylate the MAPK or ERK1/2.  The two isoforms of ERK, ERK1 or 2 
phosphorylate or activate important transcription factors ETS domain-containing protein (Elk-1) 
and tumor suppressor protein (p53) (Shaul and Seger, 2007).  
Ribosomal S6 kinase (RSK), mitogen and stress activated protein kinase (MSK), MAPK 
interacting serine/threonine-protein kinase (MNK) are other kinases that can inactivate BAD and 
inhibit apoptosis. ERK1/2 can directly activate transcription factors such as cMYC, ETS, and 
ELK, translation factors such as EIF-43BP, change chromatin modification such as histone 
deacetylase 6 (HDAC6), or activate lipid phosphatases such as PI4K2A and phospholipase A2 
(PLA2) ( Treisman, 1996; Williams et al., 2013).  The ERK pathway can self-regulate by using 
sprouty (SPRY), an inhibitor of RAS, or directly inhibit RAF, MEK, and RAS through negative 
feedback loops (Johnson et al., 2014).  The ERK pathway is self-contained as RAF1, MEK1/2, 
and other kinases loops can activate other MAPK pathways such as c-jun N-terminal kinases 
16 
(JNK) or Janus kinase (JAK)/ Signal transducer and activator of transcription protein (STAT) 
pathways or these other pathways can also activate ERK.   
1.9 Mechanisms of Pericyte Apoptosis 
 
Figure 9 PDGF-BB receptor activation and inactivation.  Sweeney et al., 2016. 
Figure 9 displays normal PDGF signaling in pericytes and what happens in diabetes.  A 
decrease in PDGFRβ signaling leads to pericyte apoptosis (Sweeney et al., 2016).  AGEs from 
hyperglycemia can directly increase ROS which can then activate the FOXO pathway and lead to 
apoptosis.  AGEs can also decrease AKT signaling through the increase of SHP1 and also 
decrease PDGFRβ signaling overall.  Increases in SHP1, a phosphatase, leads to not only 
increases in the dephosphorylation of both ERK/AKT pathways but also inactivation the 
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PDGFR-ββ phosphorylation itself (Geraldes et al., 2009).  There is also increased ROS from 
other sources that can lead to apoptosis through the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) activation (Romeo et al., 2002).  NFκB, a transcription factor, when 
activated can induce production of cell survival and proliferation (Ben-Neriah and Karen, 2011).  
Although NFκB can lead to proliferation, in type 2 diabetics with nonproliferative retinopathy 
NFkB leads to pericyte apoptosis (Romeo et al., 2002).  
 
Figure 10  PKCδ inactivation and activation by caspase 3.  Taken from Malvez et al., 2009. 
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1.10  PKCδ Signaling Pathway 
Another mechanism of apoptosis is through the PKCδ activation as shown in Figures 9 
and 10.  PKCδ and other isoforms are normally inactive in the cell and require activation by 
diacylglycerol (DAG).  After phosphorylation at the threonine and serine sites, PKCδ undergoes 
a conformational change exposing the regulatory unit and catalytic unit (Steinberg, 2004).  This 
change can allow caspase 3 to cleave the PKCδ and separate it into two units, a regulatory and 
catalytic unit (Malvez et al., 2009).  The catalytic unit translocates into the nucleus where it can 
activate transcription factors regarding apoptosis (Malvez et al., 2009).  This unit can also be 
activated without translocation to the membrane (Steinberg, 2004).  Caspase 3 not only cleaves 
PKCδ, but caspase 3 is also a substrate of active PKCδ, thus this system can operate in a 
feedback loop to regulate apoptosis (Basu, 2003).  The translocation of PKCδ into the nucleus 
can cause the inactivation of proteins, like nuclear DNA-dependent protein kinase (DNA-PK) 
(Brodie and Blumberg, 2003).  The inactivation of DNA-PK through PKCδ can result in the 
inhibition of DNA repair and enhanced DNA fragmentation (Brodie and Blumberg, 2003). 
1.11  Reactive Gliosis 
Reactive gliosis, the activation of macroglia, astrocytes and Müller glia, and microglia, 
can also play a role in inflammation and DR.  Reactive gliosis can often include proliferation, 
extracellular matrix (ECM) remodeling, hypertrophy, and expression patterns.  At first, this 
change is positive as it induces activation of proliferation signaling (Burda et al., 2014).  
However, chronic gliosis can result in scar formation, remodeling of the vasculature, and 
neuronal cell death (Burda et al., 2014).  Gliosis can have a wide range of changes involving 
different proteins.  For Müller glia and retinal astrocytes, glial fibrillary acidic protein (GFAP), 
toll like receptor 4 (TLR-4), vimentin (VIM), epidermal growth factor receptor (EGFR), 
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glutamine synthetase (GS), matrix metalloproteinase (MMP), tissue inhibitor of 
metalloproteinase (TIMP), neurocan core protein (NCAN), phosphacan (PCAN), glutamate 
aspartate transporter (GLAST), and many others (Dharmarajan, et al., 2017; Zamanian et al., 
2012).   
Intermediate filaments, like GFAP and VIM, help support the structure of cells and 
provide mechanical support for the cell membrane (Lodish et al., 2000).  Other proteins are 
involved in extracellular matrix homeostasis including; NCAN, PCAN, MMPs, and TIMPs 
(Frantz et al., 2010).  Growth factors, like EGF and colony stimulating factors (CSF), help 
maintain cell growth and function.  GLAST and GS mediate neurotransmitter, specifically 
glutamine, release and reuptake (Derouiche and Rauen, 1995).  Pattern recognition receptors 
(PRRs), like TLR-4, are important for mediating innate and humoral immunity in the body and 
retina (Lee and Kim, 2007). 
Astrocytes play a big role in reactive gliosis, as they are the main glial cell that undergoes 
changes when reactive gliosis happens in DR.  In astrocytes, GFAP, VIM, GS, and S100 
calcium-binding protein-β (S100β) are the major markers that get upregulated in the event of 
reactive gliosis (Rideta et al., 1997).  Other markers like ECM chondroitin sulfate proteoglycans 
(NCAN/PCAN), MMP, TIMP2, GLAST, and have also been found to be increased in reactive 
gliosis in astrocytes (Sofronview, 2009).  The proteoglycan production (NCAN/PCAN) in 
astrocytes following reactive gliosis inhibits axonal outgrowth and regeneration (Silver and 
Miller, 2004).  MMPs also exhibit increased expression by astrocytes, resulting in glial scar 
formation through breakdown and remodeling of the ECM along with attraction of astrocytes to 
the injured area (Hsu et al., 2008).  TIMP2, a regulator of MMPs, is highly expressed in reactive 
astrocytes suggest that they help with MMP regulation while also possibly separating damaged 
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retinal areas from undamaged areas (Agapova et al., 2003).  The GFAP and VIM are important 
intermediate filament proteins for astrocytes and the upregulation of GFAP and VIM in 
astrocytes can cause hypertrophy, activate the astrocyte and can slow down the regeneration of 
the injured area (Pekney and Nilsson, 2005).  GLAST and GS maintain glutamine regulation and 
an increase of GLAST and Gs can lead to decreased glutamate excitotocity (Maragakis and 
Rothstein, 2006).  There is an increase in growth factor release (EGF) and increased expression 
of growth factor receptors (EGFR), thus causing increased proliferation and survival signaling 
(Sardar et al., 2017).  Many inflammatory cytokines and chemokines are also released during 
reactive gliosis by the astrocytes (Sofroniew, 2009).  
Müller glia, like astrocytes, undergo proliferation, change ion transport properties, change 
in intermediate filament production, and can secrete molecules like VEGF through many of the 
same mechanisms (Dyer and Cepko, 2000).  GFAP and VIM upregulation in Müller glial cells 
causing cell shape alterations is one of the hallmarks of reactive gliosis, as there is little GFAP 
and VIM before reactive gliosis (Lewis and Fisher, 2003).  Müller glia also, like astrocytes, can 
undergo proliferation, change ion transport properties, and can secrete molecules like VEGF 
(Dyer and Cepko, 2000).  This is mostly likely induced by either the loss breakdown of the BRB 
or hyperglycemia induced apoptosis (Bringmann et al., 2006).  The growth factor release of 
VEGF, along with other angiogenic cytokines, can cause the increase of MMP’s by endothelial 
cells (Bringmann et al., 2006).  Changes in Mϋller glia can also not only increase inflammatory 
cytokine release, but it can also increase the production of nitric oxide (Bringmann et al., 2006).  
Mϋller glia cells can have decreased ion and water transport resulting in serum leakage and 
increased glutamate in the environment (Bringmann et al., 2006). 
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Changes in Müller glia and astrocytes during reactive gliosis can also cause changes in 
microglia (Dharmarajan et al., 2017).  Besides cell number, morphology, movement, and surface 
molecular changes, microglia can release cytotoxic substances, ROS, excitatory amino acids, and 
an increase in proteases, thus causing neuronal death (Kreutzberg, 1996).  The microglia have 
been shown to precede many macroglia changes and upon activation macroglia can then 
feedback to the microglia (Zeng et al., 2008).  Microglia changes can be seen 4 weeks before 
even the first change in GFAP in Müller cells (Barber et al., 2005).   
In early reactive gliosis, microglia act in a protective manner to help clean up debris and 
secrete wound healing factors (Kreutzberg, 1996).  However, in prolonged gliosis, microglia can 
bring about neuronal demise and other important cells (Streit et al., 1999).  The activation of 
microglia in DR can be seen to be caused by AGE, inflammatory signals, growth factors such as 
bone morphogenetic protein, generation of oxidative stress, or even by hyperglycemia itself 
(Grisby et al., 2014, Dharmarajan, et al., 2017).    
1.12  Inflammation 
Hyperglycemia, glycation, oxidative stress, AGE, reactive gliosis, and pericyte death can 
lead to an increase in inflammation in the retina, which may trigger gliosis (Tang and Kern, 
2011).  Inflammation is the body’s non-specific immune response to injury and often results in 
elevated metabolism, vasodilation, increased blood flow, release of cytokines and chemokines, 
cellular influx, and extravasation of fluids and cellular influx (Ferror-Milani et al., 2007).  It is 
normally an acute response and self-limiting, but in some cases these processes can become 
continuous and thus become known as chronic inflammation (Ferror-Milani et al., 2007).  
Changes in chemokine and cytokine release as seen in Figure 11 can often be the differentiation 
factors between acute and chronic inflammation.  The interleukins (IL) have a split role with IL-
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8, IL-16 along with granulocyte-colony stimulating factor (G-CSF) mainly playing a major role 
in acute inflammation while IL-1, 6, 11, 17 play an important role in both.  IL-2 through 5, IL-7, 
IL-9, IL-10, IL-12 through 15 along with interferons (IFN) gamma and alpha, tumor necrosis 
factors (TNF) alpha and beta, transforming growth factor (TGF) beta, and granulocyte 
macrophage stimulating factor (GM-CSF) all play an important role in chronic inflammation.  
There are some factors that affect both acute and chronic inflammation and may serve as 
mediators of acute versus chronic, like IL-1 (Feghali and Wright, 1997).  There are other factors 
that affect inflammation like interferon regulatory factor 8 (IRF8), cluster of differentiation 68 
(CD68), allograft inflammatory factor 1 (AIF-1/IBA-1), thrombospondin (THBS), and 
chemokine ligand 5 (CCL5) or better known as regulated on activation, normal T cell expressed 
and secreted (RANTES).         
  
Figure 11 Cytokines involved in acute versus chronic inflammation. Taken from Feghali and Wright (1997).  
 IL-1, IL-6, TNF-α, and maybe IL-8 are thought to be the more major initiators and 
mediators of acute inflammation, though they can be active in chronic inflammation as well 
(Gabay and Kushner, 1999).  IL-1 and its two isoforms, alpha and beta, trigger fever, increase 
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prostaglandin synthesis, activate T-cells, activate B cells and antibody production, initiate 
neutrophil activation and influx, and cause fibroblast proliferation (Keyel, 2014).  IL-6 is thought 
to be the main stimulator of many of the acute phase proteins (Gabay and Kushner, 1999). IL-6 
is more thought to be a systemic activator of inflammation (Gabay, 2006).  IL-6 can be anti-
inflammatory in early acute inflammation, and can cause reduction in the pro-inflammatory 
markers, like IL-1β and TNF-α (Tilg et al., 1994). Later during the inflammatory process, IL-6 is 
thought to be pro-inflammatory (Scheller et al., 2011).  IL-6 can activate and recruit neutrophils, 
but IL-6 also can recruit monocytes, like macrophages (Gabay, 2006).  IL-6 induces humoral 
responses, like T-cell activation and B-cell differentiation (Gabay, 1999).  TNFα, like IL-6, is an 
important homeostatic regulator of pathogen defense, apoptosis, tissue regeneration, and necrosis 
(Kalliolias and Ivashkiv, 2015). TNFα can recruit inflammatory cells (causing release of growth 
factors, adhesion molecules), induce necroptosis, induce other inflammatory cytokine release, 
and cause proliferation of immune cells (Kalliolias and Ivashkiv, 2015).  
Interferons, pro-inflammatory cytokines, are another major family that mediates 
inflammation.  There are two major groups of interferons, type 1 (IFNα and IFNβ) and type 2 
(IFN-γ).  Type 1 interferons are thought to be involved in maintaining T-cell regulation and 
regulating apoptosis (Akbar et al., 2000).  IFNα helps prolong T-cell activation and prevents 
apoptosis of T-cells, thus possibly providing memory in T and B cells (Akbar et al., 2000).  IFN-
γ has been shown to enhance major histocompatibility complex (MHC) class I and II expression 
while also priming and activating macrophages for phagocytosis (Feuerer et al., 2006).  MHC’s 
are important for the regulation of the innate and humoral immunity, specifically the response of 
the different T cells (Swain, 1983).  IFN-γ has been shown to transition the immune response to 
helper type 1 (Th1) rather than helper type 2 (Th2) while affecting TNFα response (Farrar and 
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Schreiber, 1993).  Th1 signals innate immune system responses recruiting and activating 
macrophage and cytotoxic T cells while producing a pro-inflammatory environment by releasing 
factors like IFN-γ and TGF-β (Singh et al., 1999).  Th2 signals the adaptive immune system 
recruiting CD4+ T cells and B cells and producing an anti-inflammatory response by releasing 
factors like IL-10 and IL-4 (Singh et al., 1999).    
 Different growth factors, like VEGF, GM-CSF, and G-CSF, have a role in the immune 
response of inflammation.  The CSF family are involved in the activation and generation of 
leukocytes from the bone marrow (like macrophages and granulocytes) (Becher et al., 2016).  
After T and often B cell infiltration caused by IL-6 or IFN-γ, GM-CSF is often released and 
stimulates the production of monocytes (macrophages and dendritic cells) and granulocytes 
(neutrophils, eosinophils, and basophils) (Becher et al., 2016).  G-CSF; however, produces and 
activates only granulocytes, primarily neutrophils (Campbell et al., 2016).  VEGF is involved in 
the formation and maintenance of blood vessels (angiogenesis) and the release of VEGF 
increases leukocyte penetration through increased vascular permeability (Zimmermann and 
Issekutz, 2006).  TGF-β plays a different role in inflammation and the immune response.  TGF-β 
maintains self-tolerance of immune cells while initiating and regulating lymphocytes, natural 
killer (NK), and macrophages (Ming, 2006).   
 Along with growth factors, there are a variety of other factors that get either upregulated 
or downregulated in inflammation.  CCL5, chemotaxis marker, is released by macrophages to 
recruit T cells to the injured area (Marques et al., 2013).  THBS is a regulatory marker, not only 
activating TGF-β but also mediating IL-10, an anti-inflammatory agent (Lopez-Dee et al., 2011).  
Interferon regulatory factor (IRF) is regulator marker that regulates the activation or repression 
of the IFN’s (Taniguchi et al., 2001).  IRF8 is induced by IFN-γ and important for myeloid cell 
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and lymphoid cell differentiation (Taniguchi et al., 2001). CD68 and IBA1 are markers for 
activated microglia and macrophages during the inflammatory process (Chiu et al., 2009). 
 Diseases, like diabetes and arthritis, often result in a chronic inflammatory state.  Pro-
inflammatory factors, such as IL-6 and TNF-α, often are elevated in diabetic patient when 
compared to their non-diabetic counterparts and correlate with insulin resistance (Navarro and 
Mora, 2006).  Obesity, associated with type 2 diabetes, impacts inflammation as adipocytes may 
cause the release of IL-6, C reactive protein (CRP), and TNFα (Dandona et al., 2004).  
Inflammation can be attributed to continuous pancreatic β cell death in type 1 diabetics (Eizirik 
et al., 2009).  The activation of pattern recognition receptors (PRR), like TLR-4, activates the 
innate immune response and increases in IFN, IL-1, and TNF (Eizirik et al., 2009).  These 
different chemokines and cytokines attracts macrophages and neutrophils which then release 
factors like Chemokine (C-C Motif) Ligand 2 (CCL2).  The increase of ER stress from activation 
of TLR may cause β cell apoptosis, which along with macrophages activation, can eventually 
lead to the activation of the adaptive immune system (Eizirik et al., 2009).  This loop continues 
and eventually leads to suppression of β cell function and proliferation, thus leading to β cell 
death (Eizirik et al., 2009). 
 Apoptosis is only one of the causes of inflammation (Tang and Kern, 2011).  
Hyperglycemia produces a pro-inflammatory environment (Tang et al., 2011).  Increases in fatty-
acid composition can cause chronic inflammation in the retina (Byeon et al., 2010).  Oxidative 
stress causes increases Il-1β and NF-κB (Kowluru and Odenbach, 2004).  AGE/RAGE increase 
the proinflammatory environment while also decreasing anti-inflammatory effects (Li et al., 
2011).             
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 Inflammation changes affect the retina and eye differently than in other parts of the body.  
CCL-2, IL-1β, TNF-α, and VEGF are just some of the inflammatory factors that have been found 
to be increased in DR (Tang and Kern, 2011).  Increases in VEGF production results in increases 
in vascular permeability and genesis of new capillaries, leading to breakdown of BRB (Tang and 
Kern, 2011).  Leukocyte migration to the BRB may trigger endothelial cell apoptosis (Joussen et 
al., 2003).  Microglia become activated in high glucose states and the microglial activation 
releases proinflammatory and cytotoxic factors (Tang et al., 2011).  Mϋller glia, through 
activated RAGE signaling, leads to VEGF and other cytokines release (Du et al., 2004).  
Pericytes, in hyperglycemia conditions, releases factors like IL-1β, NF-κB, VEGF, TNF-α, and 
TGF-β, and these factors stay increased even when there is a loss of high glucose environment 
(Kowluru et al., 2010).    
  
 
Figure 12  Hypothesis on how diabetes and hyperglycemia causes DR. Taken from Shin et al., 2014. 
1.13 Focus for study  
The inflammatory changes, along with AGE/RAGE and ROS, can often lead to the 
progressive nature of DR as seen from Figure 12.  However, the relationship between pericyte 
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loss and inflammation is not well established (Tang and Kern, 2011).  The cause of pericyte loss 
could be due to inflammation, AGE/RAGE, and/or oxidative stress.  All these changes will affect 
PDGFRβ signaling and the downstream pathways.  These changes are hard to see in humans, as 
most people who get early symptoms of DR often already the moderate to late stage DR.  
However, even with animal models, most studies are done with animals presenting after 
hyperglycemia and pericyte loss are complete.  This study addresses when various pro-
inflammatory molecules are present in relation to pericyte loss, gliosis, and vascular changes and 
directly tests a role for γ-γ in pericyte health. 
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2.  MATERIALS AND METHODS 
2.1 Isolation and Culture of Pericytes 
Pericyte cells were cultured in DMEM Sigma medium containing [a mixture of 
DMEM (D5523 Sigma), penicillin/streptomycin, glutamax, 10% FBS and 44 U/ml of 
interferon-γ (IFN-γ; R&D systems)].  In acute treatments, pericytes were grown to 
confluence with 5%CO2 at 33 °C and passaged every 2-3 days using trypsin-EDTA.  
After the plating on 6 well-plates, cells were treated with ranging from 1-100 ng/ml 
mouse interferon-gamma (IFN-γ; R&D systems), 1 μl/ml vehicle (4 mM HCL), 1μl/ml of 
PBS, or 40-80ng/ml of PDGF-BB (recombinant human PDGF-BB; R&D systems).  After 
24 hours of incubation, pericytes were either treated with IFN-γ or PBS for 24 hours.  
Then PDGF-BB or 4mM HCL was added for 30 minutes before harvesting for RNA 
isolation and protein extraction.  In chronic treatments, pericytes were plated and 
incubated between 24-48 hours.  After incubation, media was removed and washed with 
DMEM + 10%FBS before the addition of media containing IFN-γ or PBS.  Pericytes 
were treated with IFN-γ for 24 hours for 3 days.  After 72 hours of treatment, 50 ng of 
PDGF-BB or vehicle (4mM HCL) was added and incubated for 30 minutes before 
harvesting and for protein extraction, RNA isolation, or immunocytochemistry. 
2.2 Western Blotting 
Cells were washed and before being scraped and centrifuged for 10 mins at 4⁰C at 12,000 
RPM.  After incubation on ice in lysis buffer (150 mM NaCl, 50mMTris pH 8.0, 2 mM EDTA, 
5% TritonX-100; 100 mM PMSF, protease inhibitor cocktail (p50700-1, RPI corp) and 
phosphatase inhibitor cocktail (P0044, Sigma) for 15 mins protein was then for 10 mins at 4⁰C at 
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12,000 RPM.  Total protein concentration was then was determined using BCA protein Assay 
reagent (Thermo Scientific).  Five μl of sample was mixed with 500 μl of working reagent 
(prepared by mixing Pierce BCA Reagent A and B in 50: 1 ratio) and 495 μl of water. This 
solution was incubated at 65 °C for 30 min, followed by colorimetric analysis using a NanoDrop 
2000c spectrophotometer (Thermo Scientific). 50 μg of total protein mixed with the loading dye 
at a 3:1 ratio was then loaded and run on a 4%–20% SDS polyacrylamide gel (Expedeon, San 
Diego, CA) at 125 V for 1 h.  Proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad) via a wet transfer at 4⁰C for 90 mins at 100V and subjected to 
immunoblotting.  Prior to immunoblotting, some membranes was subject to Western Blot 
Enhancer Signal treatment kit (Thermo Scientific 46641).  This involved washing the membrane 
3X with ultrapure water then incubation with Antigen Pretreatment Solution for 10 mins at room 
temperature (RT) before washing 5X with ultrapure water.   The membrance was then blocked 
with either 5% milk in tris buffered saline tween 20 (TBST) or 10% BSA in TBST (TBST; 
composition – 20 mM Tris base, 137 mM sodium chloride, 1 M HCl,  0.1% Tween-20, at pH 
7.6) at RT for 1 h on a shaker. The blots were incubated with primary antibody-diluted TBST at 
4 °C overnight on a shaker.  The following day, the blots were washed 3X at 10 minutes and 1X 
at 5 minutes with TBST and incubated with HRP conjugated secondary in TBST for 1 hr at RT. 
Blots were washed 3X for 10 minutes and 1X for 5 minutes in TBST, incubated with super 
signal west femto or super signal west pico plus chemiluminescent substrate (Thermo Scientific), 




Table 1 List of Western Blot Antibodies 
Antibody WB 
concentration 
Catalog # Vendor RRID # 
Phospho-PDGFRB 1:1000 MAB9027 R&D 
Systems 
AB_2162777 
PDGFRB 1:1000 3169 CST AB_2162497 
Phospho-p44/42 MAPK 1:1000 9101 CST AB_331646 
P44/42 MAPK 1:1000 9102 CST AB_330744 
Phospho-Akt 1:1000 4060 CST AB_2315049 
Akt 1:1000 2920 CST AB_1147620 
PKC-δ Antibody 1:1000 Gtx50605 Gene Tex AB_11162869 
B-tubulin 1:1000 T0198 Sigma AB_477556 
Peroxidase-Conjugated 
Goat anti-Rabbit 





1:4000 32430 Thermo 
Scientific 
AB_1185566 
Goat anti-Rabbit IgG, 
HRP- linked antibody 
1:8000 7074 CST AB_20999233 
Horse anti-Mouse IgG 
HRP-Linked antibody 
1:8000 7076 CST AB_330924 
 
 
2.3 Flat Mount Immunohistochemistry 
Preparation of retinal flatmounts and immunolabeling was done as described in 
(Dharmarajan et al., 2017). Briefly, enucleated eyes were washed in 1× PBS, fixed in 4% PFA, 
transferred to 2× PBS on ice, and followed by retina isolation, four to five radial incisions were 
made to create a petal shape (Dharmarajan S. et al., 2017).  Retinas were transferred to cold 
methanol (−20 °C).  The tissue was washed with 1× PBS before and blocked in Perm/Block 
solution (1× PBS, 0.3% TritonX-100, 0.2% bovine serum albumin, and 5% donkey or goat 
serum) for 1hr at RT. The tissue was then washed in PBSTX (0.3% TritonX-100 diluted in 1X 
PBS) and incubated with primary antibody made in Perm/Block solution (Table 2) overnight at 4 
°C. On the following day, the tissue was washed with 2X for 10 minutes each time with PBSTX, 
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incubated with secondary antibody for 3 hours, washed with 3X for 15 minutes each time with 
PBSTX, incubated with Hoechst solution, and mounted onto a slide with Aqua Polymount 
(Polysciences, Inc). 
Table 2 List of Immunohistochemistry Antibodies 
Antibody Flatmount 
Concentration 
Catalog #  Vendor RRID# 
GFAP  1:150 Z0334  Dako AB_10013382 
Sox2  1:150 SC17320  Santa Cruz AB_22686684 
IBA1  1:150 019-19741  Wako AB_839504 
NG2  1:200 05-710  Millipore AB_309925 
IB4  1:300 I21411  Thermo Scientific AB_2314662 
Cleaved Caspase 3  1:100 AF835  R & D Systems AB_2243952 
PCNA   1:200 2586  Cell Signaling AB_2160343 
Alexa Flour  1:500 A-11034, A-
11055 





Methods were followed as decribed Dharmarajan et al., 2017.  Briefly, the cells were washed 
with 1X PBS and then fixed for 1hr in 4% paraformaldehyde (PFA).  After washing with 1X PBS, cells 
were permeabilized in methanol, incubated with 1% SDS in 0.01M PBS, and washed in 1X PBS. The cell 
were then incubated in 5% serum with 0.25% TritonX-100 in 1X PBS for 1 hour at room temperature.  
Following removal of blocking solution, cells were incubated at 4°C overnight in 2% serum in 0.025% 
Triton-X in 1XPBS with the appropriate primary antibody.  Following overnight incubation with the 
primary antibodies, the cells were washed with 1X PBS and incubated 1hr at RT with appropriate 
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secondary antibody.  The slides were then washed with 1X PBS, counterstained with Hoechst solution, 
and mounted with Aqua polymount.  
2.5 Reverse Transcriptase-quantitative Polymerase Chain Reaction 
Reverse Transcriptase-quantitave Polymerase Chain Reaction (RT-qPCR) was done 
following the procedure done by Dharmarajan et al., 2014, 2017.  Using a SYBR green mix 
(Roche), the reactions were carried out using the LightCylcer480 system (Roche). The change in 
RNA levels was measured using the 2 −ΔΔCt method, where Ct is the crossing 
threshold/crossing point (Cp) value (Dharmarajan et al., 2017).  Relative RNA levels were 
compared to the control animal and normalized using the geometric means from the Ct value 
derived from three housekeeping genes: β- 2 Microglobulin (B2M), succinate dehydrogenase 
complex subunit A (SDHA), and signal recognition particle 14 kDa (SRP14). 
Table 3 List of Gliosis Markers 
Gene Primer Sequence Product length 
Gfap2 Forward TAGCCCTGGACATCGAGATCGCC 141 
  Reverse GGTGGCCTTCTGACACGGATTTGG   
Vim Forward AGGAAGCCGAAAGCACCCTGC 78 
  Reverse TCCGTTCAAGGTCAAGACGTGCC   
Gs Forward GCGCTGCAAGACCCGTACCC 145 
  Reverse GGGGTCTCGAAACATGGCAACAGG   
Egfr-1 Forward ACCTATGCCACGCCAACTGTACCT 82 
  Reverse TGAACGTACCCAGATGGCCACACTT   
Tlr-4 Forward TGCCTGACACCAGGAAGCTTGA 102 
  Reverse AGGAATGTCATCAGGGACTTTGCTG   
Pcan Forward ATCCCTGAGTGGGGAAGGCACA 96 
  Reverse AGCAGGGGATGCTGGGTGATGA   
Ncan Forward CCTGACAAGCGTCCATTCGCCA 90 
  Reverse ACTGTCCGGTCATTCAGGCCGAT   
Timp2 Forward GCAACAGGCGTTTTGCAATG 71 
  Reverse CGGAATCCACCTCCTTCTCG   
Mmp14 Forward TGGGCCCAAGGCAGCAACTT 89 
  Reverse CGTTGTGTGTGGGTACGCAGGT   
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Table 4 List of Inflammatory Markers 
Gene Primer Sequence Product length 
Gm-Csf Forward AGTCGTCTCTAACGAGTTCTCC 178 
  Reverse AACTTGTGTTTCACAGTCCGTT   
Csf1 Forward ACCAAGAACTGCAACAACAGC 91 
  Reverse GGGTGGCTTTAGGGTACAGG   
Inf-α Forward CAAGCCATCCCTGTCCTGAG 131 
  Reverse TCATTGAGCTGCTGGTGGAG   
Inf-γ Forward CAACAGCAAGGCGAAAAAGGA 90 
  Reverse AGCTCATTGAATGCTTGGCG   
Il-1β Forward TGTCTGAAGCAGCTATGGCAA 141 
  Reverse GACAGCCCAGGTCAAAGGTT   
Il6 Forward ACTTCACAAGTCGGAGGCTT 111 
  Reverse TGCAAGTGCATCATCGTTGT   
VEGF Forward ACTGGACCCTGGCTTTACTG 74 
  Reverse CTCTCCTTCTGTCGTGGGTG   
CCl5 Forward TGCCCACGTCAAGGAGTATTT 111 
  Reverse ACCCACTTCTTCTCTGGGTTG   
Thbs1 Forward GCCACAGTTCCTGATGGTGA 149 
  Reverse TTGAGGCTGTCACAGGAACG   
Thbs2 Forward GGGAGGACTCAGACCTGGAT 105 
  Reverse CGGAATTTGGCAGTTTGGGG   
Cd68 Forward AAGGGGGCTCTTGGGAACTA 139 
  Reverse AAGCCCTCTTTAAGCCCCAC   
Iba1 Forward ACGAACCCTCTGATGTGGTC 118 
  Reverse TGAGGAGGACTGGCTGACTT   
Irf8 Forward CGGATATGCCGCCTATGACA 73 
  Reverse CTTGCCCCCGTAGTAGAAGC   
B2M Forward AGATGAGTATGCCTGCCGTG 120 
  Reverse TCATCCAATCCAAATGCGGC   
Sdha Forward GGACAGGCCACTCACTCTTAC 130 
  Reverse CACAGTGCAATGACACCACG   
Srp14 Forward CCTCGAGCCCGCAGAAAA 134 






Flatmounts of all cell counts were imaged using Olympus Fluoview FV 1000 with N=4 
or 5.  Area was subdivided into two regions up to 1500um2 from the optic nerve, or 2) the area 
from 1500-300um2 and 3-5 pictures were taken of each area.  Quantification was done using NIH 
image J (Scheinder et al., 2012) and was graphed using scatter dot function of GraphPad Prism. 
For IB4 vascular staining, the percentage area and branches were determined using AngioTool 
software (Zudaire et al., 2012).  The RT-qPCR results were calculated using the method 
described by Pfaffl (Pfaffl, 2010) and the values were normalized to a geometric mean of 3 
housekeeping genes (N=3). Log2 expression levels were calculated and graphed using Microsoft 
Excel. In western blots (N=3), densitometry was done using ImageJ and the results were graphed 
using Microsoft Excel (Scheinder et al., 2012).  Immunocytochemistry results were collected and 
graphed using the scatter dot plot function of GraphPad Prism with the average and error bars 
shown in black.  All statistical significance was determined using a one-way analysis of variance 




3.1 Pericyte loss was evident as early as 3 weeks in the Akita and DB model systems. 
The progression of retinal pericyte loss in the Akita and DB models has not been 
described.  Further, there have been few comparative analyses using models of type 1 and type 2 
diabetes.  To investigate the loss of pericytes in a model of type 1 and type 2 diabetes, retinal 
flatmounts were immunolabeled for pericyte marker neural/glial antigen 2 (NG2) at 3, 6, 12, 18, 
and 24 weeks of age in both the Akita and DB models (Figure 13A).  A comparative analysis of 
NG2+ cells indicates there were fewer cells in the Akita and DB retinas in comparison to the 
wild type (WT) as early as 3 weeks of age (Figure 13B).  Both the Akita and DB models lost 
pericytes at 12 weeks of age (Fig 13B).  The number of pericytes in the DB retinas leveled out at 
the 18 and 24 week time points; however, the number of pericytes in the Akita retina appeared to 




Figure 13 Pre-retinal pericyte numbers decrease in 2 models of DR.  A)  Retinal flatmounts from 3, 6, 12, 18, and 24 
week mice from WT, Akita, and DB mice were immunolabeled with neural/glial antigen 2 (NG2), a pericyte cell 
marker (Ozerdam et al., 2001).  Each retina was subdivided into two regions; 1) the area up to 1500um2 from the 
optic nerve, or 2) the area from 1500-300um2 from the optic nerve.  Within each region, 3-5 counts were taken using 
NIH image J (Schneider et al., 2012) and the numbers averaged together (N=5 retina/stage/genotype).   
Magnification bar = 50 µm B) Quantification of NG2+ cells were graphed using the scatter dot plot function of 
GraphPad Prism with the average and error bars shown in black. Statistical significance were determined using a 




3.2 Retinal microvasculature showed changes early in DB model system that correct 
with time 
Generally speaking, neovascularization has been proposed to occur late in the progression 
of changes that accompany DR in humans and other species (Alistar et al., 2005; Cheung et al., 
2005).  Neovasculariztion, if it occurs at all, has been shown to occur very late in both DB and 
Akita mice (Cheung et al., 2005, Robinson et al., 2012).  No studies to date have done a careful 
quantitative analysis of the retinal microvasculature in a type 1 or a type 2 model of diabetes 
throughout the development of the disease.  To investigate the retinal vasculature, retinal flat 
mounts from 3, 6, 12, 18 week-old mice were immunolabeled with the endothelial cell marker 
isolectin B4 (IB4) (Figure 14A). Images of the retina were analyzed for the percentage of the 
retinal area labeled with IB4 and the number of branches using AngioTool software (Zudaire et 
al., 2012). In regards to percentage of area covered by IB4+ vasculature, there were significant 
increases in vessel area in the DB mice at 3 and 6 weeks in comparison to the WT littermate 
controls (Figure 14B).  The percentage of area covered by the IB4+ cells decreased to control 
levels in the 12 week DB retinas and remained at the same level in the 18 week retinas. In the 
Akita retina, total area covered by the IB4+ vasculature did not deviate from those of the WT 
littermates at any of the ages examined (Figure 14B). A quantitative analysis of branching in the 
DB retina indicated an increase in branching at all time points examined in comparison to WT 
retinas (Figure 14C).  However, the Akita mice had increased branching only at 6 weeks but no 




Figure 14.  Pre-retinal microvasculature changes occur early in DB model   A) Retinal flatmounts at 3, 6, 12, 18, and 
24 week WT, Akita, and DB mice were immunolabeled with isolectin B4 (IB4), an endothelial cell marker (Ernst et 
al., 2006).  Magnification bar = 50 µm  B) To perform measurements on the retinal vasculature, the retina were 
again subdivided into two sections (0-1500um2 and 1500-3000um2 from the optic nerve) and the percentage of 
retinal area covered by vasculature were determined using AngioTool software (Zudaire et al., 2012) (N=4 
retinas/stage/genotype).  C) Using the same regions of the retina, vascular branch numbers were determined using 
AngioTool software (Zudaire et al., 2012).  Graphs in B and C were plotted using GraphPad Prism and the statistical 
significance were determined using a one-way ANOVA with a Tukey’s multiple comparison test (* p,0.05; ** p< 
0.01; *** p<0.0001). 
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3.3 Gliosis was present early in the progression of the disease 
In addition to pericyte loss, DR is also accompanied by retinal astrocyte and Müller cell 
gliosis (Fletcher et al., 2007).  Some studies have indicated that gliosis may occur prior to 
changes in the vasculature (Fletcher et al., 2007, Roque et al., 1990).  To determine what stages 
gliosis might be occurring in each model system in comparison to WT controls, expression 
patterns of molecules that have been associated with gliosis were examined using RT-qPCR 
(Dharmarajan et al., 2014 and references therein).  As can be seen in Figure 15, mRNA encoding 
epidermal growth factor receptor (Egfr), toll-like receptor 4 (Tlr4), phosphacan (Pcan), and 
tissue inhibitor of metalloproteinase 2 (Timp2) are upregulated more than 1.5 fold (0.58 in log2 
scale) at 3 weeks in the Akita retinas.  Increases in gene expression appear to peak at the 12 week 
time point and are reduced thereafter (Figure 15). 
In comparison, some of the gliosis markers, including glutamine synthetase (Gs), Egfr, 
neurocan (Ncan) and matrix metalloproteinase 14 (Mmp14) were actually downregulated in the 
DB retinas in comparison to control levels (as indicated by levels below 0).  By 6 weeks, many 
markers were expressed at levels well above the controls, including glial fibrillary acidic protein 
(Gfap), S100b, vimentin (Vim), Egfr, Pcan, and Mmp14.  In the DB samples, the gliosis appeared 





Figure 15 Gliosis in Akita mice increase as early as 3 weeks. Expression levels of a panel of gliosis markers were 
analyzed by RT-qPCR in RNA samples from retina samples in 3, 6, 12, and 18 week aged mice.  Retinas were 
isolated and 2.5ng of original RNA was used.  Quantitation was done using the method by Pfaffl, 2010 (Pfaffl, 
2010).  Expression levels were normalized to a geometric mean of 3 housekeeping genes, β- 2 Microglobulin (B2m), 
succinate dehydrogenase complex subunit A (Sdha), and signal recognition particle 14 kDa (SRP14).  RNA levels of 
Akita mice were compared relative to WT littermates. Bars above a level of (0.58) represent an increase of over 1.5 
fold change (significant increase) in mRNA levels while bars below the level of 0 represent a decrease in mRNA 
levels relative to the corresponding vehicle control.  At 3 weeks, there is a significant decrease in Vim and Ncan 
while Mmp14, Timp2, Tlr4, and Egfr.  At the 6 week time point, there is a significant increase in mRNA expression 
in Gfap.  At the 12 week mark, many gliosis markers have significant increased expression, with only S100, Gs, 
Pcan, not showing increased levels when compared to their WT counterparts.  At the 18 week mark, there is a 
decrease in mRNA levels of many markers, although have over 1.5 fold change when compared to their WT 
counterparts.  Abbreviations: Gfap glial fibrillary acidic protein, Gs-glutamine synthetase, S100-calcium-binding 
protein B, Vim-Vimenten, Egfr- epidermal growth factor receptor, Tlr4-toll like receptor 4, Ncan-neurocan, Pcan-






























Figure 16 Gliosis in DB mice increase as early as 6 weeks. Expression levels of a panel of gliosis markers were 
analyzed by RT-qPCR in RNA samples from retina samples in 3, 6, 12, and 18 week aged mice.  Retinas were 
isolated and 2.5ng of original RNA was used.  Quantitation was done using the method by Pfaffl, 2010 (Pfaffl, 
2010).  Expression levels were normalized to a geometric mean of 3 housekeeping genes, β- 2 Microglobulin (B2m), 
succinate dehydrogenase complex subunit A (Sdha), and signal recognition particle 14 kDa (SRP14).  RNA levels of 
DB mice were compared relative to WT littermates. Bars above a level of (0.58) represent an increase of over 1.5 
fold change (significant increase) in mRNA levels while bars below the level of 0 represent a decrease in mRNA 
levels relative to the corresponding vehicle control.  At 3 weeks, there is a significant decrease in Ncan and Mmp14.  
At the 6 week time point, there is a significant increase in mRNA expression in Gfap, S100, Vim, Egfr, Pcan, and 
Mmp14.At the 12 week mark, many of these markers stay increased along with Ncan, although Vim does almost 
reach WT levels.  At the 18 week mark, there is an increase in Gs and Tlr while Vim, Ncan, and S100 decrease back 
to the control mRNA levels.  Abbreviations: Gfap glial fibrillary acidic protein, Gs-glutamine synthetase, S100-
calcium-binding protein B, Vim-Vimenten, Egfr- epidermal growth factor receptor, Tlr4-toll like receptor 4, Ncan-
neurocan, Pcan-phosphocan, Timp2- tissue inhibitor of matix metalloproteinases 2, Mmp- matrix metalloproteinase. 
 
Proliferation of astrocytes can sometimes accompany gliosis (Sardar et al., 2017; Selmaj 
et al., 1990).  To determine if retinal astrocytes were proliferating in either model, retinal flat 
mounts from 3, 6, 12, 18, and 24 week DB and Akita retinas were immunolabeled with astrocyte 
and progenitor marker SOX2 (Figure 17A).  Quantitative analysis of astrocyte numbers indicated 
there was no increase to the number of SOX2+ cells in the DB or Akita samples in comparison to 































Figure 17 Pre-retinal astrocyte numbers do not change in Akita or DB model system in comparison to WT 
littermates.  A) Retinal flatmounts at 3, 6, 12, 18, and 24 week from WT, Akita, and DB mice were immunolabeled 
for sex determining region y (SRY) -box 2 (SOX2), an astrocyte and progenitor cell marker (Ellis et al., 2004).  
Each retina was subdivided into two regions; 1) the area up to 1500um2 from the optic nerve, or 2) the area from 
1500-300um2 from the optic nerve.  Within each region, 3-5 counts was taken using NIH image J (Schneider et al., 
2012) and the numbers averaged together (N=5 retina/stage/genotype).   Magnification bar = 50 µm 
B) Quantification of SOX2+ cells was graphed using the scatter dot plot function of GraphPad Prism with the 
average and error bars shown in black. Statistical significance was determined using a one-way analysis of variance 





3.4 Proinflammatory mRNA levels are increased as early as 6 weeks in Akita and 
DB models 
Clearly, there are changes to pericyte number in both Akita and DB models by 3 weeks 
(Figure 16).  It is unclear when inflammatory changes occur to the retina of each model system; 
however, there are known to be increases in proinflammatory markers, particularly at later stages 
of DR (Tung and Kern, 2011; Tang et al., 2011, Byeon et al., 2010).  To determine when 
increases in proinflammatory markers were present in the retina of Akita and DB models mRNA 
levels of specific markers were investigated using RT-qPCR at 3, 6, 12, and 18 weeks.    
In the Akita retina, pro-inflammatory mRNA levels at the 6 week time point significantly 
increase in Csf, Ifnγ, Il6, Vegf, Ccl5, and Thbs1.  Expression of many those markers increased or 
stayed at a similar level at the 12 week time point and was joined by increases in Gmcsf, Ifnα, 
Il1β, Thbs2, and Iba1 (Figure 18). Twelve weeks appears to have been the peak in changes to 
mRNA levels, thereafter there was a decrease in mRNA levels.    
The DB model differed from the Akita model in that several mRNAs appeared to have 
mRNA levels below that of WT controls at 3 weeks, including Csf, Ifnα, Ifnγ, Vegf, and Thbs1 
(Figure 19).  At 6 weeks, there were moderate increases in levels of Ifnα, Ifnγ, Il1β, Vegf, Ccl5, 
Thbs1, and Iba1.  The mRNAs for the proinflammatory markers appeared to peak around 12-18 
weeks (Figure 19).  Three markers (Ifnγ, Ccl5, and Cd68) showed a decrease at 12 weeks, 




Figure 18 Proinflammatory markers increase at 6 weeks for Akita mice.  Expression levels of a panel of 
inflammatory markers were analyzed by RT-qPCR in RNA samples from retina samples in 3, 6, 12, and 18 week 
aged mice Akita and WT.  Retinas were isolated and 2.5ng of original RNA was used.  Quantitation was done using 
the method by Pfaffl, 2010 (Pfaffl, 2010).  Expression levels were normalized to a geometric mean of 3 
housekeeping genes, β- 2 Microglobulin (B2m), succinate dehydrogenase complex subunit A (Sdha), and signal 
recognition particle 14 kDa (Srp14).  RNA levels of Akita mice were compared relative to WT littermates. Bars 
above a level of (0.58) represent an increase of over 1.5 fold change (significant increase) in mRNA levels while 
bars below the level of 0 represent a decrease in mRNA levels relative to the corresponding vehicle control.  At 3 
weeks, there no major increases or decrease of proinflammatory mRNA expression.  Abbreviations: CD; cluster of 
differentiation, Csf;colony  stimulating factor, Gm-csf; granulocyte macrophage colony stimulating factor, Ifn; 
interferon, Il; interleukin, Tnf-α; tumor necrosis factor alpha, Thbs; thrombospondin, Vegf; vascular endothelial 



























Figure 19 Proinflammatory markers increase at 6 weeks for DB mice.  Expression levels of a panel of inflammatory 
markers were analyzed by RT-qPCR in RNA samples from retina samples in 3, 6, 12, and 18 week aged DB and 
WT mice.  Retinas were isolated and 2.5ng of original RNA was used.  Quantitation was done using the method by 
Pfaffl, 2010 (Pfaffl, 2010).  Expression levels were normalized to a geometric mean of 3 housekeeping genes, β- 2 
Microglobulin (B2m), succinate dehydrogenase complex subunit A (Sdha), and signal recognition particle 14 kDa 
(SRP14).  RNA levels of DB mice were compared relative to WT littermates.  RNA levels of DB mice were 
compared relative to WT littermates. Bars above a level of (0.58) represent an increase of over 1.5 fold change 
(significant increase) in mRNA levels while bars below the level of 0 represent a decrease in mRNA levels relative 
to the corresponding vehicle control. Abbreviations: CD; cluster of differentiation, Csf;colony  stimulating factor, 
Gm-csf; granulocyte macrophage colony stimulating factor, Ifn; interferon, Il; interleukin, Tnf-α; tumor necrosis 
factor alpha, Thbs; thrombospondin, Vegf; vascular endothelial growth factor, Irf; interferon regulating factor, Iba1; 
ionized calcium-binding adaptor molecule 1. 
 
As tight junctions fail during DR, cells from the immune system have been shown to 
infiltrate the blood-retinal barrier, and some of those cells are capable of differentiating into 
macrophage and microglial cells (Streit et al., 1996).  To investigate whether any of the changes 
in mRNA or protein levels of proinflammatory proteins was due to an increase in myeloid 
lineage cells, retinal flat mounts from Akita and DB mice were immunolabeled at 3, 6, 12, 18, 
and 24 weeks with antibody specific for myeloid-lineage specific protein IBA1 (Figure 20A).   
IBA1+ cells were quantified in images taken from these samples (Figure 20B).  In the Akita 
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however, in the DB samples there was a small decrease at 3 weeks, followed by an increase at 12 
weeks in comparison to WT retinas (Figure 20B).  
 
Figure 20 Numbers of pre-retinal IBA1+ microglial cells. A) Retinal flatmounts at 3, 6, 12, 18, and 24 week  from 
WT, Akita, and DB mice were immunolabeled for myeloid lineage marker IBA1 (Ito et al., 1998).   Each retina was 
subdivided into two regions; 1) the area up to 1500um2 from the optic nerve, or 2) the area from 1500-300um2 from 
the optic nerve.  Within each region, 3-5 counts was taken using NIH image J (Schneider et al., 2012) and the 
numbers averaged together (N=5 retina/stage/genotype). Magnification bar = 50 µm B) Quantification of IBA1+ 
cells was graphed using the scatter dot plot function of GraphPad Prism with the averageand error bars shown in 
black. Statistical significance was determined using a one-way (ANOVA) with a Tukey’s multiple comparison test 
(* p<0.05). 
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3.5 PDGFRβ signaling is not altered in pericytes acutely treated with IFN-γ. 
Our previous results indicated there was an increase in IFN-γ at the mRNA level for 
Akita and DB models as well as protein levels in the DB model.  IFN-γ is of interest for several 
reasons; 1) it is a potent proinflammatory factor that communicates with cells of the immune 
system to encourage their infiltration into the nervous system (Feuerer et al., 2006; Singh et al., 
1999;), 2) it has been shown to decrease PDGFRβ signaling in human pericytes obtained from 
epileptic patients (Jansson et al., 2016), and 3) it has been shown to increase activation of PKCδ 
in some cell types (Deb et al., 2003; Shen et al., 2003). Although a reduction in PDGFRβ 
signaling and an activation of PKCδ would be consistent with changes described in pericytes of 
diabetic retinas that lead to apoptosis, neither of these changes have been associated specifically 
with inflammation in DR.   
To investigate whether IFN-γ can trigger changes in survival associated with PDGFRβ 
signaling and/or PKCδ, isolated pericytes were treated with increasing levels of IFN-γ.  
Furthermore, we devised a system in vitro in which the effects of acute or chronic exposure to 
IFN-γ could be tested.  In the acute trials, pericytes were treated with various concentrations of 
IFN-γ for 24 hours, followed by treatment with PDGFBB, while in the chronic trials pericytes 
were treated with IFN-γ for 72 hours, followed by PDGFBB.  This paradigm was used to 
determine the effect of IFN-γ on PDGFRβ signaling or its downstream pathways.  In order to 
determine differences between total protein levels and activated levels, antibodies specific to the 
phosphorylated AKT (pAKT), ERK (pERK), and PDGFRβ (pPDGFRβ) along with antibodies 
specific to the protein AKT, ERK, and PDGFRβ.  In the acute treatments, pericytes were treated 
with 24 hours with 25, 50, and 100ng of IFN- γ and then for 30 mins with 50 ng of PDGFBB 
(Figure 21, 22, 23).  IFN-γ treated pericytes decreased pAKT levels in 1 day treatments as seen 
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in Figure 21B.  At the highest concentration, pAKT activity was decreased.  The total protein 
levels were not changed.  Even at early stages of pericyte treatment, IFN-γ decreased the activity 
of AKT while not changing the total protein levels in the cells.  IFN-γ treatment at higher 
concentration only slightly decreased total PDGFRβ levels but did not change the activity 
pPDGFRβ levels (Figure 22 B and Figure 22C). Acute IFN-γ treatment increases total ERK 




Figure 21 Acute exposure to IFN-γ does not change levels of AKT or pAKt.  A) Retinal pericytes were treated for 
24 hours with 0 (veh), 25, 50, or 100ng of IFN-γ.  After 24 hours of exposure to vehicle or IFN-γ, cells were treated 
with 50ng of PDGF BB for 30 minutes and protein lysates were examined for levels of pAKT, total AKT, and β 
tubulin levels (N=3) Densitomeric measurements were performed on the immunoblots using NIH image J 
(Scheinder et al., 2012).  B) Densitometric analysis of pAKT normalized to levels of total AKT.  C) Densitometric 
analysis of AKT normalized to levels of βtubulin.  Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon 




Figure 22 Acute exposure to IFN-γ does not change levels of total PDGFRβ or pPDGFRβ. A) Retinal pericytes were 
treated for 24 hours with 0 (veh), 25, 50, or 100ng of IFN-γ followed by 30 minute exposure to veh or 50 ng of 
PDGF-BB. Protein lysates were probed with antibodies specific to pPDGFRβ, total PDGFRβ, or β tubulin. (N=3) 
Densitomeric measurements were performed on the immunoblots using NIH image J (Scheinder et al., 2012) and the 
statistical significance was analyzed by one-way ANOVA on the resulting normalized densitometric measurements.  
B) Densitometric analysis of pPDGFRβ normalized to total PDGFRβ.  C) Densitometric analysis of PDGFRβ 
normalized to β tubulin. Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon Gamma, PDGFRβ-




Figure 23 Acute exposure to IFN-γ increases total ERK levels but does not increase pERK levels.  A) Retinal 
pericytes were treated for 24 hours with 0 (veh), 25, 50, or 100ng of IFN-γ followed by 30 minute exposure to veh 
or 50 ng of PDGF-BB. Protein lysates were probed with antibodies specific to pERK, total ERK, or β tubulin (N=3).  
Densitomeric measurements were performed on the immunoblots using NIH image J (Scheinder et al., 2012) and the 
statistical significance was analyzed by one-way ANOVA on the resulting normalized densitometric measurements.  
B) Densitometric analysis of pERK normalized to total ERK.  C) Densitometric analysis of total ERK normalized to 
β tubulin. (* p < 0.05; **p< 0.01).  Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon Gamma, ERK-




  3.6 pAKT levels were decreased following chronic treatments with IFN-γ  
Diabetes can cause a chronic inflammatory state and this can cause angiogenesis seen in 
DR (Dandona et al., 2003; Jackson et al., 1997).  It has also been shown that chronic 
inflammation have produce different responses can acute inflammation (Gabay and Kushner, 
1999; Byeon et al., 2010).  Even though there was very little change in the activity and amount 
of protein expression PDGFRβ or the downstream targets of ERK and AKT, there has been 
studies done that have shown in chronic conditions IFN-γ does affect PDGFRβ (Jannsson et al., 
2016).  In order to mimic chronic conditions, pericytes were treated with IFN-γ instead every 24 
hours for a total of 72 hours of 1, 25, and 50 ng. PDGFBB was then added for 30 mins and the 
cells were collected for protein analysis (Figure 24, 25, 26).  PDGFRβ, AKT and ERK, both total 
protein levels and active protein levels were looked at to see if the chronic IFN-γ treatments had 
different effects than the acute treatments.   
pAKT signaling significantly decreased in chronic IFN-γ treatment as seen in Figure 25, 
unlike the acute conditions.  In the 1 and 25 ng chronic IFN-γ treatments with PDGF-BB there 
was very little change in pAKT signaling at 1 and 25 ng levels, but in the 50 ng IFN-γ and 
PDGFBB there was a significant decrease in AKT activity when compared to the PDGF-BB 
treated pericytes alone.  There were no changes in normal protein expression levels across the 
treatments, however, as seen in Figure 24B suggesting that IFN-γ only changes activity of the 




Figure 24 Chronic exposure to high levels of IFN-γ decreases levels of pAKT.  A) Retinal pericytes were treated for 
72 hours with 0, 1, 25, or 50ng of IFN-γ.  After 72 hours of exposure to vehicle or IFN-γ, cells were treated with 
50ng of PDGF BB for 30 minutes and protein lysates were examined for levels of pAKT, total AKT, and β tubulin 
levels. (N=3) Densitomeric measurements were performed on the immunoblots using NIH image J (Scheinder et al., 
2012) and the statistical significance was analyzed by one-way ANOVA on the resulting normalized densitometric 
measurements.  B) Densitometric analysis of pAKT normalized to levels of total AKT. (* p< 0.05) C) Densitometric 
analysis of AKT normalized to levels of βtubulin.  Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon 





3.7 PDGFRβ and ERK signaling do not change following chronic treatment with IFN-γ 
pPDGFRβ expression did not change in chronic IFN-γ treatments as seen in Figure 25B.  
There was a slight but statistically insignificant decrease in total PDGRβ seen Figure 25C but the 
activity of the protein did not change.  IFN-γ treatments chronically, like the acute treatments, 
did not change the activity of the receptor or amount of receptor. 
There was also no change in pERK or normal ERK expression levels in chronic 
treatments as seen from Figure 26 B and C.  The addition of IFN-γ and PDGF-BB did not change 




Figure 25 Chronic exposure to IFN-γ does not change levels of total PDGFRβ or pPDGFRβ. .  A) Retinal pericytes 
were treated for 72 hours with 0 (veh), 25, 50, or 100ng of IFN-γ followed by 30 minute exposure to veh or 50 ng of 
PDGF-BB. Protein lysates were probed with antibodies specific to pPDGFRβ, total PDGFRβ, or β tubulin. (N=3)  
Densitomeric measurements were performed on the immunoblots using NIH image J (Scheinder et al., 2012) and the 
statistical significance was analyzed by one-way ANOVA on the resulting normalized densitometric measurements.  
B) Densitometric analysis of pPDGFRβ normalized to total PDGFRβ.  C) Densitometric analysis of PDGFRβ 
normalized to β tubulin. Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon Gamma, PDGFRβ-




Figure 26. Chronic exposure to IFN-γ does not change levels of ERK or pERK.  A) Retinal pericytes were treated 
for 72 hours with 0 (veh), 25, 50, or 100ng of IFN-γ followed by 30 minute exposure to veh or 50 ng of PDGF-BB. 
Protein lysates were probed with antibodies specific to pERK, total ERK, or β tubulin (N=3).  Densitomeric 
measurements were performed on the immunoblots using NIH image J (Schneider et al., 2012) and the statistical 
significance was analyzed by one-way ANOVA on the resulting normalized densitometric measurements.  B) 
Densitometric analysis of pERK normalized to total ERK.  C) Densitometric analysis of total ERK normalized to β 
tubulin. Abbreviations: Veh-Vehicle, PBB- PDGF-BB, IFN-γ-Interferon Gamma, ERK-extracellular signal-




3.8 IFN-γ induces PKCδ cleavage in chronic treatments 
Increased levels of active PKCδ in relation to DR have been described by other 
investigators (Geraldes and King, 2010).  However, increased PKCδ activity was not assessed at 
early stages of DR when pericytes were undergoing apoptosis (Geraldes and King, 2010), and no 
inflammatory pathways have been specifically connected to the rise in PKCδ activity.  There is 
some evidence that IFN-γ can increase PKCδ activity in some cells (Uddin et al., 2002, Gumina 
et al., 1991); however it has not been investigated in pericytes. PKCδ has been found to be 
activated in hyperglycemic conditions and negatively regulates AKT activity (Li et al., 2006; 
Robinson et al., 2012).  PKCδ increases SHP-1 activity, which can in turn dephosphorylate ERK, 
AKT, and even PDGFRβ (Geraldes et al., 2009).  To determine if IFN-γ treatment can alter 
either total PKCδ levels or levels of active PKCδ, pericytes treated chronically with 1, 25, or 
50ng of IFN-γ followed by vehicle or PDGFBB.  Protein lysates were then investigated using an 
antibody which will recognize the full c-terminus of the length protein as well as the cleaved 
activated form of the protein PKCδ (Oh et al., 2004). There is an increase in both total PKCδ 




Figure 27 Levels of PKCδ appear to increase following chronic exposure to IFN-γ.  Pericytes were treated for 72 
hours with 0 (veh), 1, 25, or 50 of IFN-γ followed by 30 minute exposure to vehicle or 50 ng of PDGF-BB.  Protein 
lysates were immunoblotted and probed for antibodies specific for PKCδ. Abbreviations: Veh-Vehicle, PBB- 




3.9 IFN-γ increased cell death in pericytes without affecting division 
 Hyperglycemia has been found to decrease survival and increase cell apoptosis in other 
cell types (Inge et al., 2010; Krankel et al., 2005).  This would be consistent with our chronic 
condition data.  Under chronic conditions, pericytes displayed both increased PKCδ activity and 
decreased AKT phosphorylation, without affecting PDGFRβ or ERK activity or levels.  There 
was also increased cleaved PKCδ levels in chronic conditions.  Active caspase 3 cleaves PKCδ 
while also being a regulator in apoptosis activity (Porter et al., 1999; Basu, 2003).  AKT can both 
upregulate proliferation signaling and downregulate apoptotic signaling (Brunet et al., 2001).  
Proliferating cell nuclear antigen (PCNA) is a protein that has been associated with active 
proliferation (Hall et al., 1990).  To determine whether there were changes to proliferation and/or 
apoptosis, pericytes treated chronically with 1, 25, or 50ng of IFN-γ followed by vehicle or 
PDGFBB.  Pericyte were then labeled using an antibody specific for proliferating cell nuclear 
antigen (PCNA) or cleaved caspase 3.   
From Figure 28, there was no change in the percentage of PCNA cells with the addition 
of PDGF-BB or IFN-γ.  IFN-γ or PDGF-BB does affect proliferation in pericytes in chronic 
conditions. From Figure 29, there was significant increases in cleaved caspase 3 activity in IFN-γ 
treatments.  As the amount of IFN-γ increased, so does the amount of caspase 3+ cells.  At 1ng 
IFN-γ treatment, approximately 5% cells displayed active caspase 3 but, at the 50ng IFN-γ this 
number jumps to 15%.  PDGF-BB does not affect caspase 3 activity, as there are no differences 




Figure 28 PCNA activity does not change with IFN-γ treatment.  Pericytes were treated for 72 hours with 0 (veh), 1, 
25, or 50 of IFN-γ followed by 30 minute exposure to vehicle or 50 ng of PDGF-BB.  Cells were collected then 
immunolabeled with PCNA (N=3). Percentage of PCNA+ cells over total cells was graphed using the scatter dot plot 
function of GraphPad Prism with the average and error bars shown in black. Statistical significance was determined 





Figure 29 Cleaved caspase 3 activity increased with the addition of IFN-γ.  Pericytes were treated for 72 hours with 
0 (veh), 1, 25, or 50 of IFN-γ followed by 30 minute exposure to vehicle or 50 ng of PDGF-BB.  Cells were 
collected then immunolabeled with cleaved caspase 3 (N=3). Percentage of cleaved caspase 3+ cells over total cells 
was graphed using the scatter dot plot function of GraphPad Prism with the average and error bars shown in black. 
Statistical significance was determined using a one-way analysis of variance (ANOVA) with a Tukey’s multiple 







In the two mouse models, there are several early changes that have not been shown in the 
literature.  Pericyte loss was evident as early as 3 weeks in both mouse models and there was 
changes in retinal vasculature of DB mice as early as 3 weeks and at 6 weeks in the Akita mice.  
Gliosis was present in the early progression of diabetes and many of the proinflammatory 
markers increase as early as 6 weeks.  There were no substantial proliferation changes in 
astrocytes and microglia, although there were increases in activity level.   
IFN-γ appeared to regulate apoptosis in isolated pericytes without regulatory mitosis.  
The increase in apoptosis revolved around an increase in active levels of cleaved PKCδ.  At 
higher levels, the active cleaved PKCδ increased apoptosis by reducing the activity of AKT; 
however, there were no changes in the activity of ERK or PDGFRβ.  Lastly, changes in PCKδ 
and AKT were seen in chronic IFN-γ conditions, but not following acute treatments.   
4.2 Two diabetic models display different disease progression 
The two diabetic models have different patterns of DR disease progression.  Although 
both mouse models have increased hyperglycemia as early as 4 weeks, the Akita mice are not 
obese compared to their WT counterpart throughout their lifespan while DB, even at 3 weeks, 
weigh more.  The Akita models have decreased insulin in the blood (hypoinsulinemia) while, DB 
mice have increased insulin levels (hyperinsulinemia) (Yoshioka et al., 1997; Coleman, 1978). 
Insulin can contribute to differences seen in the reactivity of different glial cells (Gardner et al., 
2002; Villacampa et al., 2013; Haurigot et al., 2009). 
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Both the DB and Akita mice show a decreased pericyte count as early as 3 weeks and 
these numbers remain at control levels.  There seems to be a recovery of pericytes numbers at 18 
weeks for the Akita mice, followed by a reduction in pericyte numbers at 24 weeks.  The early 3 
week decrease could be caused by either pericyte apoptosis or decreased pericyte recruitment 
signaling from the neural crest.  Inflammation changes at 12 and 18 weeks in the Akita mice 
could allow for proliferation in pericyte numbers at 18 weeks. At the 12 week mark in the Akita 
mice, there are marked increases in ECM molecules like NCAN and MMP14, growth factors like 
CSF and GM-CSF, increase in recruitment molecules like CCL5, and an in regulatory factors 
like IRF8.  There is increased gliosis in Müller glia, microglia, and astrocytes, without a 
corresponding increase in cell numbers of macroglia (Müller glia and astrocytes) and microglia.  
This increase in activity, along with the release of growth factors, has been shown to increase 
signaling in progenitor’s cells and cause proliferation of astrocytes and endothelial cells (Burda 
and Sofronview, 2014).          
The differences in pericyte loss along with changes in glial activty could explain why the 
two models have differences in vascular structure as well.  The decreased pericyte number 
throughout DB mice would correlate with the increased branching and some early vasculature 
area.  Pericytes are important for the stabilization and maintenance of the retinal vasculature and 
their loss could result in enlarged vessels and decreased stability of these vessels, as shown from 
the increased branches and vasculature changes in early stage DB mice (Hellstrom et al., 2001; 
Sweeney et al., 2016; Bergers and Song, 2005).  As the DB mice age, there might be some 
compensatory mechanism that helps restore vasculature area.  The Akita mice only show 
significant branching at the 6 week mark could mean that obesity and/or the underlying 
metabolic disorder plays a major difference in vasculature changes. 
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In the two mouse models, there are few changes in microglia and astrocyte numbers, but 
there is significant change in astrocyte and microglia activity.  There are however, small changes 
in microglia numbers as DB mice have increased microglia at 12 week and a decrease at 3 week 
while the Akita mice show no changes in microglia number at all.  Activated microglia enhance 
phagocytosis, proliferation, migration, and can induce release of cytokines like TNFs, IL-6 
(Langmann, 2007).  This is consistent with the increased mRNA levels Cd68 and Iba1 along 
with Tlr4 and Il6.   
There are very important changes seen in DB mice that have not been the described in 
literature in pericytes.  Most pericyte loss and vascular changes in DB mice have been shown to 
occur at 6 months stage, while in our study there are changes as early as 3 weeks (Linwincz et 
al., 1990; Chou et al., 2014).  There is a decrease in mRNA levels of ECM molecules, Mmp14 
and Ncan at early stages and a decrease in many proinflammatory markers like Ifnγ, Il6, and 
Vegf.  This would suggest that DB mice have an anti-inflammatory environment early in their 
life.  It has been shown in other models that a lack of leptin function can impair immunity, 
through a decreased spleen and thymus function (Wellen and Hotamisligil, 2005).  Starting at 6 
weeks, after hyperglycemia and obesity start to increase, there is an increase in proinflammatory 
markers and some gliosis markers.  At 12 and 18 weeks, there is a significant increase in the 
mRNA levels of proinflammatory and gliosis markers.  The increase in activity in other cells can 
cause changes associated with inflammation (Burda and Sofronview, 2014).   
In the Akita mice, there are differences in disease progression in comparison to DB mice.  
Even though there is a decrease in pericyte numbers as early as 3 weeks, there is no 
corresponding vasculature change at 3 weeks.  There is also pericyte recovery at 18 weeks, 
which was not seen in the DB mice.  The inflammation pattern is very similar to DB mice after 
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hyperglycemia initiates, as there is an increases in many proinflammatory markers at 6 weeks.  
There is a concomitant increase in mRNA levels of gliosis markers at 12 weeks.  This evidence 
suggests that glucose level is not the only factors influencing the pathology of DR, but obesity 
may also play a role.          
4.3 Downstream effects of PDGFRβ changed in IFN-γ treatments 
In the in-vivo studies of pro-inflammatory markers, we determined that there was an 
increase in IFN-γ mRNA and protein.  Further studies were focused on the role of IFN-γ in 
pericyte survival. PDGF-BB treatment activates PDGFRβ and causes activation of ERK and 
AKT, which was used as our positive control (Chaudhary and Hruska, 2001).  There were some 
major differences in acute treatments and chronic treatments in affecting PDGFRβ signaling.  
Both treatments had small but statistically insignificant decreases in overall PDGFRβ expression, 
though the activity of the receptor did not appear to change measurably.  In the chronic 
treatments; however, there is decreased levels of pAKT, while the pAKT levels in the acute 
treatments did not appear to change.  High levels of IFN-γ appear to cause an increase in 
apoptosis, specifically using the P13K/AKT pathway as there was no change in ERK signaling in 
both the chronic and acute conditions.  There is an increase in the overall ERK levels at the acute 
treatment was not present following chronic treatment with IFN-γ. 
The acute phase increase in overall ERK expression with the lack of change in 
phosphorylation suggests the cells could be undergoing apoptosis.  While AKT has been found 
to be very anti-apoptotic, ERK has been found to be activated in both survival and apoptosis.  
ERK signaling promotes anti-apoptotic proteins, such as B-cell lymphoma 2 (BCL-2), myeloid 
leukemia cell differentiation protein (MCL-1), inhibitor of apoptosis (IAP) and represses pro-
apoptotic proteins, BAD and BCL-2-like protein 11 (BIM) (Cagnol and Chambard, 2009).  
66 
 
However, ERK has also been shown to activate apoptosis through caspase-8 activation or 
cytochrome c release (Cagnol and Chambard, 2009). 
It has been found that hyperglycemia does increase activation of both SHP-1 and and 
PKCδ (Geraldes et al., 2009).  SHP-1, a well-known phosphatase, can negatively regulate AKT, 
ERK, and PDGFRβ signaling under some circumstances; however, we did not detect a 
measurable change in pERK or pPDGFRβ (Lodeiro et al., 2011).  PKCδ and AKT have been 
shown to regulate each other in other models (Li et al., 2006; Gao et al., 2008, Tanak et al., 
2003).  The activity and even amount of PKCδ was increased as IFN-γ was added in our 
pericytes.  PKCδ has been shown to increase apoptosis its nuclear translocation and subsequent 
activation of p53 and release of cytochrome c (Coutinho et al., 2009).  The release of cytochrome 
c increases cleavage and activity of caspase 3, which was seen in the chronic IFN-γ treatments 
(Liu et al., 2015). Cell proliferation; however, was not affected by chronic IFN-γ treatment.  This 
suggests that inflammation does play a role in pericyte cell death, similar to what Jansson et al. 
found in their study (2016).  However, Jansson et al. found a decrease in PDGFRβ, AKT, and 
ERK signaling which we did not detect (2016).  This could be due to a couple of reasons.  
Animal models of diseases progress differently than humans as mouse models have not been 
found to fully replicate chronic human inflammatory diseases (Seok et al., 2013).  The pericytes 
used by Jansson et al. were isolated from human patients with epilepsy while our pericytes were 
from obtained from a diabetic mouse model (2016).  Epilepsy can induce changes like increased 
pericyte loss, changes in astrocyte and endothelial cells, and changes in inflammation itself 





4.5 Future Directions 
IFN-γ specifically activates the janus kinase (JAK) and signal transducers and activators 
of transcription (STAT), specifically JAK 1 and JAK2 into STAT1.  JAK1 and JAK2 along with 
STAT1 should be furthered studies to see the effects of their roles in apoptosis, PKCδ, and 
PDGFRβ in pericytes IL-6 treatments should be done to see if this apoptosis and AKT signaling 
is STAT-1 specific or if STAT3 and other STAT’s can also produce similar results (Rawlings et 
al., 2004).  Other growth factors involved in angiogenesis, like VEGF, can also be looked at to 
see if this pathway is similarly affected.  IFN-γ, as found in our study, does not directly affect 
PDGFRβ signaling, but it does affect PKCδ and AKT activity.  There could be other pathways 
that IFN-γ affects that were not examined.  TNF-α has been shown to interact with IFN-γ (Gabay 
et al., 1999; Loddenkemper et al., 2006; Tilg et al., 1994).  A combination of different pro-
inflammatory factors, like TNF-α with IFN-γ, in PDGFRβ signaling in pericytes as well as 
pericyte survival.     
 In-vivo studies may not have the same effect as in-vitro studies.  PDGFRβ signaling in 
both animal models should be looked at in-vivo to see if similar results as seen by in-vitro 
results. Pericyte loss should be further examined in 3 week mice to determine the exact cause.  
Cytochrome c and caspase activity should be looked at in 3 week mice to determine if pericyte 
loss is due to apoptosis.  Assays that determine the activity of recruitment should be looked in 3 
week mice to determine if this loss is due to lack of signaling, as other studies have shown that 
injections of PDGF-BB can cause abnormal modeling of the developing vasculature (Benjamin 
et al., 1998). Insulin levels play a big role in development of DR disease and the effects of 
insulin needs to be looked at to see if it has a role in pericyte cell death or signaling.   
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Although mouse models are good for early disease modeling in DR, they are not great 
models for late stage pathogenesis of DR.  Retinal neovascularization, which does occur in 
humans, does not occur in mice unless induced through ischemia or having a specific targeted 
VEGF mutation (Grossniklaus et al., 2010). One reason could be due to mice are resistant to 
getting high blood pressure (hypertension) and formation of plaques in the arteries 
(atherogenesis) unless induced through targeted gene mutations (Breyer et al., 2004; Leong et al., 
2015).  Diabetic mouse models, like Akita and DB mice, lack renal failure that can be found in 
long-term diabetes (Breyer et al., 2004).  Mouse models lack the clathrin heavy chain on 
chromosome 22 (CHC22) protein, which is important for glucose transport (Vassilopoulos et al., 
2009).  It is one or several of these differences in species why mouse models do not get the 
advanced stages of diabetes and DR, seen in humans.  Further studies on DR and pericyte loos 
should be done on mouse models exhibiting both diabetes and one of the other factors, like renal 
failure or high blood pressure, to look at a better model for DR disease progression and more 
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